# OnCo record aml-npm1-kmt2a (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/aml-npm1-kmt2a/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "aml-npm1-kmt2a" ;
  schema:name "NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia"@en ;
  schema:alternateName "NPM1-mutated AML"@en, "KMT2A-rearranged AML"@en, "MLL-rearranged AML"@en, "Menin-dependent AML"@en ;
  schema:description "NPM1-mutated and KMT2A-rearranged leukaemias depend on a protein called menin to keep leukaemia genes switched on. Menin inhibitors, revumenib and ziftomenib, are the first drugs to exploit this, and they produce remissions in patients whose leukaemia had come back after everything else."@en ;
  schema:url <https://onco.cc/cancers/aml-npm1-kmt2a/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Nucleophosmin> ;
  schema:citation <https://en.wikipedia.org/wiki/Nucleophosmin>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1411> ;
  onco:tag "subtype-page" ;
  onco:technologies <https://onco.cc/technologies/menin-inhibitors/> ;
  onco:targets <https://onco.cc/targets/menin/>, <https://onco.cc/targets/npm1/>, <https://onco.cc/targets/kmt2a/> ;
  onco:pathways <https://onco.cc/pathways/menin-kmt2a/> ;
  onco:terms <https://onco.cc/terms/differentiation-syndrome/>, <https://onco.cc/terms/eln-risk/>, <https://onco.cc/terms/mrd/> ;
  onco:pipeline <https://onco.cc/drugs/revumenib/>, <https://onco.cc/drugs/ziftomenib/>, <https://onco.cc/drugs/bleximenib/>, <https://onco.cc/technologies/menin-inhibitors/>, <https://onco.cc/trials/myelomatch/> ;
  onco:standardOfCare <https://onco.cc/drugs/cytarabine-7-3/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/technologies/ngs-mrd-clonoseq/>, <https://onco.cc/terms/eln-risk/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/azacitidine/>, <https://onco.cc/trials/viale-a/>, <https://onco.cc/pairings/menin-plus-venetoclax-hma/>, <https://onco.cc/drugs/revumenib/>, <https://onco.cc/drugs/ziftomenib/>, <https://onco.cc/trials/augment-101/>, <https://onco.cc/trials/komet-001/>, <https://onco.cc/technologies/allogeneic-hsct/> .